Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | SWI:SNF matrix associated | 0.00322436 | 0.5 | 0.5 |
Onchocerca volvulus | 0.00322436 | 0.5 | 0.5 | |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.00322436 | 0.5 | 0.5 |
Schistosoma mansoni | brg-1 associated factor | 0.00322436 | 0.5 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.00322436 | 0.5 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.00322436 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.00322436 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.00322436 | 0.5 | 0.5 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.00322436 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.00322436 | 0.5 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.00322436 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.00322436 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.00322436 | 0.5 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.00322436 | 0.5 | 0.5 |
Loa Loa (eye worm) | brahma associated protein | 0.00322436 | 0.5 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.00322436 | 0.5 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.00322436 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.00322436 | 0.5 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.00322436 | 0.5 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.00322436 | 0.5 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.00322436 | 0.5 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.00322436 | 0.5 | 0.5 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.00322436 | 0.5 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.00322436 | 0.5 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.00322436 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | 1.779 uM | ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye | ChEMBL. | 20485428 |
EC50 (functional) | = 1.78 uM | Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye | Saint Jude. | 20485428 |
EC50 (functional) | = 3.45 uM | Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye | Saint Jude. | 20485428 |
EC50 (functional) | 3.4504 uM | ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye | ChEMBL. | 20485428 |
Inhibition (functional) | = 0 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 1.76 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 2.14 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 3.81 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 14 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 46 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 93 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 1.48 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = -5 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 14 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 46 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 93 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 108.6 % | Plasmodium falciparum 3D7 % growth inhibition at 7uM as measured by YOYO-3 red dye | Saint Jude. | 20485428 |
Percent growth inhibition (functional) | = 113.2 % | Plasmodium falciparum 3D7 % growth inhibition at 7uM as measured by SYBR green dye | Saint Jude. | 20485428 |
XC50 (functional) | = 6 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 0.99785 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 20485428 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.